Results 31 to 40 of about 17,400 (182)

Catheter-directed therapy to treat intermediateand high-risk pulmonary embolism: Personal experience and review of the literature

Cardiology Journal, 2023
Pulmonary embolism (PE) is the third leading cause of cardiovascular death in the western world. Prompt recognition, risk stratification, and individualized treatment are crucial to improve outcomes in patients with PE.
Arkadiusz Pietrasik, Aleksandra Gasecka, Aleksander Kotulecki, Paulina Karolak, Aleksander Araszkiewicz, Szymon Darocha, Marcin Grabowski, Marcin Kurzyna   +7 more
doaj   +1 more source

Pulmonary Embolism Response Teams: A Novel Approach for the Care of Complex Patients With Pulmonary Embolism [PDF]

Clinical and Applied Thrombosis/Hemostasis, 2018
Pulmonary embolism represents the third most common cause of cardiovascular death in the United States. Reperfusion therapeutic strategies such as systemic thrombolysis, catheter directed therapies, surgical pulmonary embolectomy, and cardiopulmonary support devices are currently available for patients with high- and intermediate-high–risk pulmonary ...
Mateo Porres–Aguilar, Javier E. Anaya-Ayala, Gustavo A. Heresi, Belinda N. Rivera-Lebron   +3 more
openaire   +2 more sources

New Diagnostic Tools for Pulmonary Embolism Detection

Methodist DeBakey Cardiovascular Journal
The presentation of pulmonary embolism (PE) varies from asymptomatic to life-threatening, and management involves multiple specialists. Timely diagnosis of PE is based on clinical presentation, D-dimer testing, and computed tomography pulmonary angiogram
Jacob Shapiro, Adam Reichard, Patrick E. Muck   +2 more
doaj   +1 more source

Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium

Clinical and Applied Thrombosis/Hemostasis, 2019
Pulmonary embolism (PE) is a life-threatening condition and a leading cause of morbidity and mortality. There have been many advances in the field of PE in the last few years, requiring a careful assessment of their impact on patient care.
Belinda Rivera-Lebron MD, MS, FCCP, Michael McDaniel MD, FACC, FSCAI, Kamran Ahrar MD, MBA, Abdulah Alrifai MD, David M. Dudzinski MD, Christina Fanola MD, MSC, Danielle Blais PharmD, BCPS-AQ Cardiology, David Janicke MD, PhD, Roman Melamed MD, FCCP, Kerry Mohrien PharmD, BCPS, Elizabeth Rozycki PharmD, BCPS, Charles B. Ross MD, FACS, Andrew J. Klein MD, Parth Rali MD, Nicholas R. Teman MD, Leoara Yarboro MD, Eugene Ichinose MD, Aditya M. Sharma MBBS, Jason A. Bartos MD, PhD, Mahir Elder MD, FACC, FSCAI, FCCP, Brent Keeling MD, Harold Palevsky MD, Soophia Naydenov MD, FCCP, Parijat Sen MBBS, MD, Nancy Amoroso MD, Josanna M. Rodriguez-Lopez MD, George A. Davis Pharm D, Rachel Rosovsky MD, Kenneth Rosenfield MD, MHCDS, FACC, FSCAI, Christopher Kabrhel MD, MPH, James Horowitz MD, Jay S. Giri MD, MPH, Victor Tapson MD, FCCP, FRCP, Richard Channick MD,   +34 more
doaj   +1 more source

Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients [PDF]

Clinical and Experimental Emergency Medicine, 2016
The diagnosis or exclusion of pulmonary embolism (PE) remains challenging for emergency physicians. Symptoms can be vague or non-existent, and the clinical presentation shares features with many other common diagnoses.
Daniel Corrigan, Christiana Prucnal, Christopher Kabrhel   +2 more
doaj   +1 more source

Real World Practices of Interhospital Transfer in Pulmonary Embolism: A Pulmonary Embolism Response Teams Consortium Observational Study

Pulmonary Circulation
Treatment options for acute pulmonary embolism (PE) have evolved rapidly, with an increasing number of interventional options, necessitating interhospital transfer for consideration of advanced therapies and optimal care.
Ka U. Lio, Michael McDaniel, Paul Yacono, Belinda Rivera‐Lebron, Rachel Rosovsky, Mary Jo Farmer, Steven Horbal, Charles B. Ross, Parth Rali   +8 more
doaj   +1 more source

The Development of Rheumatoid Arthritis‐Specific Ambulatory Care Sensitive Conditions: Results of a Consensus Process

Arthritis Care &Research, Accepted Article.
Objective Ambulatory care sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin, Candace H. Feldman, Claire E.H. Barber, Gabriel Fabreau, Jake Jennings, Scott Patten, Cheryl Barnabe, Inflammatory Arthritis‐Specific ACSC Consensus Process Working Group   +7 more
wiley   +1 more source

Biomarkers of Thrombo-Inflammatory Responses in Pulmonary Embolism Patients With Pre-Existing Versus New-Onset Atrial Fibrillation

Clinical and Applied Thrombosis/Hemostasis, 2021
Pulmonary embolism (PE) patients have an increased prevalence and incidence of atrial fibrillation (AF). Because comorbid AF increases risk of morbidity and mortality, we sought to investigate the role of thrombo-inflammatory biomarkers in risk ...
Dimpi Patel BA, Amir Darki MD, Debra Hoppensteadt PhD, Iman Darwishw BA, Mushabbar Syed MD, Yevgeniy Brailovsky DO, Jawed Fareed PhD   +6 more
doaj   +1 more source

Shape Memory Polymer‐Based Flexible Pressure Sensor for Real‐Time Venous Thrombosis Monitoring

Advanced Materials Interfaces, EarlyView.
A shape‐memory tubular flexible pressure sensor with a 100‐mesh microstructured SMP‐PLA/MWCNTs sensing layer was developed for PICC‐mounted monitoring of thrombosis‐related pressure changes. The sensor combines high sensitivity (204 kPa−1), a fast response time (28 ms), and conformal catheter fixation and was validated by hydrostatic and ex vivo ...
Yi Chen, Mengtao Huang, Ang Wang, Linsen Tang, Mengting He, Xuejin Li, Shaoxing Qu, Zongrong Wang   +7 more
wiley   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source